Regulatory T Cell Responses to Interleukin-2 administrated immediately after modified radical mastectomy in breast cancer patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004716

Enrollment

Unknown

Registered

2014-05-23

Start date

2014-06-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

rhIL-2 group:surgery and rhIL-2

control group:surgery

Eligibility

Sex/Gender

Female

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were modified radical mastectomy for primary breast cancer diagnosed by biopsy, aged 20-60years in the Third Xiangya Hospital .

Exclusion criteria

Exclusion criteria: Exclusion criteria were previous breast cancer surgery (except diagnostic biopsy), inflammatory breast cancer, received chemotherapy and/or radiotherapy before surgery, ASA (American Society of Anesthesiologists) Physical Status III-IV or greater, complicated with diseases of immune system or endocrine system, and long-term medication with effect on immune or endocrine system.

Design outcomes

Primary

Measure	Time frame
the percentage of Tregs /CD4 T cell;real-time PCR of Foxp;	—

Contacts

Public ContactWen Ouyang

The Third Xiangya Hospital of Central South University

ouyangwen133@vip.sina.com+86 13974934441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026